Jiangsu Hengrui Pharmaceuticals announced that the company and its subsidiaries recently received multiple drug clinical trial approval notices from the National Medical Products Administration for HRS-4642 injection, Atezolizumab injection, SHR-1826 injection, and other drugs, and will conduct clinical trials in the near future.
恒瑞医药：获多项临床试验批准通知书
Jiangsu Hengrui Pharmaceuticals: Received multiple clinical trial approval notifications.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated